Deconstruction of non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1 for exploration of the optimization landscape of fragments

Journal of Medicinal Chemistry

Volumn 54, Issue 3, 2011, Pages 709-718

  Brandt, Peter ^a   Geitmann, Matthis ^a   Danielson, U Helena ^a,b  

^a Beactica   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEIN;

ABSENCE; ANALYSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; CALCULATION; CONFORMATION; CONFORMATIONAL TRANSITION; DISSOCIATION; DRUG BINDING; DRUG EFFICACY; DRUG INTERACTION; ENERGY; EXPLORATORY BEHAVIOR; FEE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE DEFICIENCY; LANDSCAPE; LIGAND BINDING; NONHUMAN; PRODUCTIVITY; PROTEIN INTERACTION; VIRUS TYPING;

ANTI-HIV AGENTS; BINDING SITES; HIV REVERSE TRANSCRIPTASE; HIV-1; MODELS, MOLECULAR; PROTEIN BINDING; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 79851482963     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101052g     Document Type: Article

References (43)

1. Erlanson, D. A.; McDowell, R. S.; O'Brien, T. Fragment-based drug discovery. J. Med. Chem. 2004, 47, 3463-3482. (Pubitemid 38822007)
2. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A. J. Recent developments in fragment-based drug discovery. J. Med. Chem. 2008, 51, 3661-3680. (Pubitemid 351956496)
3. de Kloe, G. E.; Bailey, D.; Leurs, R.; de Esch, I. J. P. Transforming fragments into candidates: small becomes big in medicinal chemistry. Drug Discovery Today 2009, 14, 630-646.
4. Leach, A. R.; Hann, M. M.; Burrows, J. N.; Griffin, E. J. Fragment screening: an introduction. Mol. BioSyst. 2006, 2, 429-446.
5. Hubbard, R. E.; Chen, I.; Davis, B. Informatics and modeling challenges in fragment-based drug discovery. Curr. Opin. Drug Discovery Dev. 2007, 10, 289-297. (Pubitemid 46800223)
6. Everts, S. Piece by piece. Chem. Eng. News 2009, 86, 15-23.
7. Gill, A. New lead generation strategies for protein kinase inhibitors: fragment based screening approaches. Mini-Rev. Med. Chem. 2004, 3, 301-311. (Pubitemid 38854872)
8. Geitmann, M.; Elinder, M.; Seeger, C.; Brandt, P.; de Esch, I. J. P.; Danielson, U. H. Identification of a novel scaffold for allosteric inhibition of wild type and drug resistant HIV-1 reverse transcriptase by fragment library screening. J. Med. Chem. DOI: 10.1021/jm1010513.
9. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discovery Today 2004, 9, 430-431. (Pubitemid 38510559)
10. Reynolds, C. H.; Bembenek, S. D.; Tounge, B. A. The role of molecular size in ligand efficiency. Bioorg. Med. Chem. Lett. 2007, 17, 4258-4261. (Pubitemid 47028600)
11. Reynolds, C. H.; Tounge, B. A.; Bembenek, S. D. Ligand binding efficiency: trends, physical basis, and implications. J. Med. Chem. 2008, 51, 2432-2438. (Pubitemid 351628504)
12. Bembenek, S.D.;Tounge, B. A.;Reynolds,C.H.Ligand efficiency and fragment-based drug discovery. Drug Discovery Today 2009, 14, 278-283.
13. For a recent paper on fragment-based deconstruction of inhibitors, see the following: Barelier, S.; Pons, J.; Marcillat, O.; Lancelin, J.-M.; Krimm, I. Fragment-based deconstruction of Bcl-xL Inhibitors. J. Med. Chem. 2010, 53, 2577-2588.
14. Geitmann, M.; Unge, T; Danielson, U. H. Biosensor-based kinetic characterization of the interaction betweenHIV-1 reverse transcriptase and non-nucleoside inhibitors. J.Med. Chem. 2006, 49, 2367-2374.
15. Geitmann, M.; Unge, T; Danielson, U. H. Interaction kinetic characterization of HIV-1 reverse transcriptase non-nucleoside inhibitor resistance. J. Med. Chem. 2006, 49, 2375-2387.
16. Geitmann, M.; Danielson, U. H. Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis. Bioorg. Med. Chem. 2007, 15, 7344-7354. (Pubitemid 47539143)
17. Elinder, M.; Nordström, H.; Geitmann, M.; Hämäläinen, M.; Vrang, L.; Öberg, B.; Danielson, U. H. Screening for NNRTIs with slow dissociation and high affinity for a panel of HIV-1 RT variants. J. Biomol. Screening 2009, 14, 395-403.
18. Danielson,U.H. Fragment library screening and lead characterization using SPR biosensors. Curr. Top. Med. Chem. 2009, 9, 1725-1735.
19. Liu, T.; Lin, Y.; Wen, X.; Jorrisen, R. N.; Gilson, M. K. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 2007, 35, D198-D201. (Pubitemid 46056198)
20. Chen, X.; Lin, Y.; Liu,M.; Gilson,M. K. The binding database: data management and interface design. Bioinformatics 2002, 18, 130-139. (Pubitemid 34145041)
21. de Kloe, G. E.; Retra, K.; Geitmann, M.;Källblad, P.; Smit, A. B.; van Muijlwijk-Koezen, J. E.; Leurs, R.; Irth, H.; Danielson, U. H.; de Esch, I. J. P. Surface plasmon resonance biosensor based fragment screening using acetylcholine binding protein identifies ligand efficiency hot spots (LE hot spots) by deconstruction of nicotinic acetylcholine receptor alpha7 ligands. J. Med. Chem. 2010, 53, 7192-7201.
22. Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A. The maximal affinity of ligands. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9997-10002. (Pubitemid 29422500)
23. Definition of ligand efficiency by Peter Kenny: (pIC50-logP)/nHA described at http://fbdd-lit.blogspot.com.
24. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discovery 2007, 6, 881-890. (Pubitemid 350042396)
25. Keserü, G. M.; Makara, G. M. The influence of lead discovery strategies on the properties of drug candidates. Nat. Rev. Drug Discovery 2009, 8, 203-212.
26. Page, M. I.; Jencks, W. P. Entropic contributions to rate accelerations in enzymic and intramolecular reactions and the chelate effect. Proc. Nat. Acad. Sci. U.S.A. 1971, 68, 1678-1683.
27. Jencks, W. P. On the attribution and additivity of binding energies. Proc. Nat. Acad. Sci. U.S.A. 1981, 78, 4046-4050. (Pubitemid 11010286)
28. Andrews, P. R.; Craik, D. J.; Martin, J. L. Functional group contributions to drug-receptor interactions. J. Med. Chem. 1984, 27, 1648-1657. (Pubitemid 15177908)
29. Ŝtrajbl, J. V.; Glennon, T. M.; Sham, Y. Y.; Chu, Z. T.; Warshel, A. How important are entropic contributions to enzyme catalysis? Proc. Nat. Acad. Sci. U.S.A. 2000, 97, 11899-11904.
30. Borsi, V.; Calderone, V.; Fragai, M.; Luchinat, C.; Sarti, N. Entropic contribution to the linking coefficient in fragment based drug design: a case study. J. Med. Chem. 2010, 53, 4285-4289.
31. Murray, C. W.; Verdonk, M. L. The consequences of translational and rotational entropy lost by small molecules on binding to proteins. J. Comput.-Aided Mol. Des. 2003, 16, 741-753. (Pubitemid 36336183)
32. Chang, C. A.; Chen, W.; Gilson, M. K. Ligand configurational entropy and protein binding. Proc. Nat. Acad. Sci. U.S.A. 2008, 104, 1534-1539.
33. Zhou, H.-X.; Gilson, M. K. Theory of free energy and entropy in noncovalent binding. Chem. Rev. 2009, 109, 4092-4107.
34. Lou,H.;Sharp,K.Onthe calculationof absolutemacromolecularbinding free energies. Proc. Nat. Acad. Sci. U.S.A. 2002, 99, 10399-10404.
35. NNRTI 1: Chan, J. H.; Freeman, G. A.; Tidwell, J. H.; Romines, K. R.; Schaller, L. T.; Cowan, J. R.; Gonzales, S. S.; Lowell, G. S.; Andrews, C. W., 3rd; Reynolds, D. J.; St Clair, M.; Hazen, R. J.; Ferris, R. G.; Creech, K. L.; Roberts, G. B.; Short, S. A.; Weaver, K.; Koszalka, G. W.; Boone, L. R. Novel benzophenones as nonnucleoside reverse transcriptase inhibitors of HIV-1. J. Med. Chem. 2004, 47, 1175-1182 (Pubitemid 38229119)
36. NNRTI 2: Bell, F.W.; Cantrell, A. S.; Hoegberg, M.; Jaskunas, S. R.; Johansson, N. G.; Jordan, C. L.; Kinnick, M. D.; Lind, P.;Morin, J. M., Jr. Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs. J. Med. Chem. 1995, 38, 4929-4936.
37. NNRTI 3: Zhang, Z.; Xu,W.; Koh, Y. H.; Shim, J.H.;Girardet, J. L.;Yeh, L. T.;Hamatake, R. K.;Hong, Z.Anovel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 2007, 51, 429-437. (Pubitemid 46185257)
38. Paris, K. A.; Haq, O.; Felts, A. K.; Das, K.; Arnold, E.; Levy, R. M. Conformational landscape of the human immunodeficiency virus type 1 reverse transcriptase non-nucleoside inhibitor binding pocket: lessons for inhibitor design from a cluster analysis of many crystal structures. J. Med. Chem. 2009, 52, 6413-6420.
39. Sarafianos, S. G.; Marchand, B.; Das, K.; Himmel, D. M.; Parniak, M. A.; Hughes, S. H.; Arnold, E. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol. 2009, 385, 693-713.
40. Ren, J.; Esnouf, R.; Hopkins, A.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure 1995, 3, 915-926.
41. Kohlstaedt, L. A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256, 1783-1790.
42. Hajduk, P. J. Fragment-based drug design: how big is too big? J. Med. Chem. 2006, 49, 6972-6976. (Pubitemid 44885985)
43. Liu, T.; Lin,Y.;Wen,X.; Jorrisen, R. N.;Gilson,M. K. BindingDB: a web-accessible database of experimentally determined proteinligand binding affinities. Nucleic Acids Res. 2007, 35, D198-D201. (Pubitemid 46056198)